Inhibikase Therapeutics stock analysis
Want to see IKT full AI Analyst Report?
Inhibikase Therapeutics (IKT) Stock Price & Analysis
IKT Stock Chart & Stats
- Day’s Range
- $1.49 - $1.58
- 52-Week Range
- $1.40 - $2.61
- Previous Close
- $1.53
- Volume
- N/A
- Average Volume (3M)
- 636.65K
- Market Cap
- $213.21M
- Enterprise Value
- $211.39M
- Total Cash (Recent Filing)
- $193.32M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.85
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strengthened Equity Base
Effectively zero debt reduces solvency and interest-burden risk while the expanded equity base provides financial support for clinical development. This gives Inhibikase greater flexibility to fund operations and pursue its lead program without the constraints associated with heavy leverage.
Late-stage Clinical Progress
A broad, actively enrolling Phase 3 program represents meaningful advancement toward a potential commercial product. Orphan designation and the 505(b)(2) pathway may streamline development and regulatory review, improving the program’s strategic position over the next several quarters.
Strengthened Clinical And Regulatory Expertise
Adding an independent director with experience developing and securing approval for cardiovascular and metabolic drugs can strengthen oversight during a pivotal trial. His background is relevant to clinical execution, regulatory strategy, and preparation for potential commercialization.
Bears Say
Pre-revenue Business Model
With no reported product revenue, Inhibikase remains dependent on financing while it advances clinical candidates. The absence of recurring operating revenue means commercial progress is still contingent on successful development and approval, leaving the business exposed to execution risk.
Rapidly Widening Losses
The accelerating loss trajectory reflects rising spending before commercialization and reduces the company’s ability to support itself through operations. Persistently larger losses can require additional capital, extend the path to profitability, and increase pressure on future financial resources.
Increasing Cash Burn And Funding Risk
Growing operating cash outflows indicate that reported losses are translating into substantial cash consumption as clinical work advances. Unless spending moderates or revenue begins, continued burn may require future equity or other financing, creating dilution and capital-raising risk.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
What is Inhibikase Therapeutics’s market cap?
When is Inhibikase Therapeutics’s upcoming earnings report date?
How were Inhibikase Therapeutics’s earnings last quarter?
Is Inhibikase Therapeutics overvalued?
Does Inhibikase Therapeutics pay dividends?
What is Inhibikase Therapeutics’s EPS estimate?
How many shares outstanding does Inhibikase Therapeutics have?
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Inhibikase Therapeutics Stock Smart Score
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Mark T. Iwicki
- Employees
- 35
- Website
- www.inhibikase.com
- Address
- 1000 N. West Street, Wilmington, DE, 19801, US
Inhibikase Therapeutics (IKT) Earnings & Revenues
IKT Earnings Call
Earnings Call SentimentNeutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.
View all IKT earnings summariesIKT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 14 |
| Technical Analysis | 1 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |













